World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 3 July 2012
Main ID:  EUCTR2011-003038-14-NL
Date of registration: 31/05/2012
Prospective Registration: Yes
Primary sponsor: GETAID
Public title: A RANDOMIZED CONTROLLED TRIAL INVESTIGATING TAILORED TREATMENT WITH INFLIXIMAB FOR ACTIVE LUMINAL CROHN'S DISEASE
Scientific title: A RANDOMIZED CONTROLLED TRIAL INVESTIGATING TAILORED TREATMENT WITH INFLIXIMAB FOR ACTIVE LUMINAL CROHN'S DISEASE - TAILORIX
Date of first enrolment: 21/06/2012
Target sample size: 120
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-003038-14
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: no Single blind: yes Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: yes Other specify the comparator: Same medical product at different dosage Number of treatment arms in the trial: 3  
Phase: 
Countries of recruitment
Netherlands
Contacts
Name: DETRE PATRICIA   
Address:  1 AVENUE CLAUDE VELLEFAUX 75010 PARIS France
Telephone: 33142494988
Email: arc.getaid@gmail.com
Affiliation:  GETAID
Name: DETRE PATRICIA   
Address:  1 AVENUE CLAUDE VELLEFAUX 75010 PARIS France
Telephone: 33142494988
Email: arc.getaid@gmail.com
Affiliation:  GETAID
Key inclusion & exclusion criteria
Inclusion criteria:
- Age > 18 years
- Active CD (CDAI>220) and signs of active inflammation as evidenced by elevated serum hsCRP levels (>5 mg/L) and/or elevated fecal calprotectin levels (>250 µg/g) and endoscopically visible ulcers.
- Patients must be naïve to biologics with indication for starting anti-TNF therapy in accordance with national reimbursement criteria.
- Patients must be naïve to thiopurines or have failed therapy with thiopurines (in which case AZA will be continued).
- Ongoing steroids are allowed if at stable dose for at least 2 weeks and at a maximum of prednisone 40 mg/d or budesonide 9 mg/day.
- Patients who consent to receiving Infliximab 5 mg/kg at week 0, 2 and 6 and further on every 8 weeks in conjunction with azathioprine (2,5 mg/kg/day). Patients who develop AZA intolerance during the trial are continued in the trial without AZA (ie IFX monotherapy).

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 110
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion criteria:
- Absence of endoscopically visible ulcers
- Prior exposure to infliximab (other biologics allowed)
- Ongoing steroid therapy at doses > 40 mg/d prednisolone equivalent
- Previous intolerance to azathioprine leading to drug discontinuation
- Ongoing infections
- Positive tuberculosis screen per local guidelines
- Serious other diseases including cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer
- Indication for immediate surgery
- Pregnant or breast-feeding woman.
- Positive fecal culture for Salmonella, Shigella, Yersinia and Campylobacter and/or presence of Clostridium difficile B toxin in the stools
- Active tuberculosis
- Untreated latent tuberculosis



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Luminal active Crohn's Disease
MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders
Therapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]
Intervention(s)

Trade Name: INFLIXIMAB
Product Name: INFLIXIMAB
Pharmaceutical Form: Suspension for infusion
INN or Proposed INN: INFLIXIMAB
CAS Number: 170277-31-3
Current Sponsor code: INFLIXIMAB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-

Primary Outcome(s)
Main Objective: To investigate whether sustained trough levels of IFX can be achieved using IFX trough level measurements and adjustment of dosing based upon these levels by means of two different standardized algorythms in comparison with ‘standard of care’ IFX treatment and its effects on clinical and endoscopic outcomes
Primary end point(s): Proportion of patients in corticosteroid-free remission (no steroids beyond week 26), with endoscopic healing at week 54 and without surgery for the full year.
Secondary Objective: • Clinical remission (CDAI <150) at each visit and the whole study period
• Endoscopic evaluation at week 0, 12 and 54
Timepoint(s) of evaluation of this end point: week 54 after inclusion
Secondary Outcome(s)
Secondary end point(s): Each visit for clinical remission
Week 0, week 12 and week 54 for endoscopic evaluation
Timepoint(s) of evaluation of this end point: Each visit
Week 0, week 12 and week 54 for endoscopic evaluation
Secondary ID(s)
2010-2
Source(s) of Monetary Support
Janssen Biologics
MERCK
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history